Have people really considered what they are interviewing for?

Quote
Anonymous said:
Alkermes Shares Sinking Lower, Down 2.1%
Published on Mon, 04/20/2015 - 11:42
Click to expand...

We rate Alkermes Plc.’s stock as sell not just because of the insider stock trade by James but also in accordance with OctaFinance’s proprietary equities trend-following model as depicted on the chart below. Just over the last 75 days, Alkermes Plc.’s share price have dived by 15.87% and is in a downtrend.
 






Anonymous said:
We rate Alkermes Plc.’s stock as sell not just because of the insider stock trade by James but also in accordance with OctaFinance’s proprietary equities trend-following model as depicted on the chart below. Just over the last 75 days, Alkermes Plc.’s share price have dived by 15.87% and is in a downtrend.
Click to expand...

Thanks for the insight. I will buy an additional 100 shares now that the price is down.
 






Anonymous said:
We rate Alkermes Plc.’s stock as sell not just because of the insider stock trade by James but also in accordance with OctaFinance’s proprietary equities trend-following model as depicted on the chart below. Just over the last 75 days, Alkermes Plc.’s share price have dived by 15.87% and is in a downtrend.
Click to expand...

Another Jackass commenter that is clueless. The stock this past August was at $40 per share now as $60. By my count that's a $20 increase per share over the past 9 months.
Not a bad return if you ask me. I will buy more as well..
 












Anonymous said:
BUSINESS
Johnson & Johnson’s Schizophrenia Drug Wins FDA Approval
Once-quarterly treatment of Invega Trinza longest dosing interval available
Click to expand...

Well, it's over before it started.

Who wouldn't want to use a 3 month injection over a monthly. It would be pretty hard to keep a straight face and tell a prescriber than a monthly is better, considering that the Invega molecule is already well proven.
 












Not your worry now is it - if you did not get an offer, you did not have to make the difficult decision wether to take such a difficult job. Move on, let those that had the choice and made it - prove you wrong.
 






Anonymous said:
Well, it's over before it started.

Who wouldn't want to use a 3 month injection over a monthly. It would be pretty hard to keep a straight face and tell a prescriber than a monthly is better, considering that the Invega molecule is already well proven.
Click to expand...

Clearly someone who does not sell in this space. Two key points genius, 1. Invega and AL are 2 completely different molecules.Invega does not work for every patient. 2. Side Effects- 3 month option is good in theory however these types of patients are often on multiple AED's and other meds. It's optimal to see the patient sooner than 3 months to re evaluate and adjust dose and other meds if necessary.
 






Anonymous said:
Clearly someone who does not sell in this space. Two key points genius, 1. Invega and AL are 2 completely different molecules.Invega does not work for every patient. 2. Side Effects- 3 month option is good in theory however these types of patients are often on multiple AED's and other meds. It's optimal to see the patient sooner than 3 months to re evaluate and adjust dose and other meds if necessary.
Click to expand...

People over oversimplifying the fact that the only reason to see a patient is the injection. You forget the heterogeneity of the disease. You're still going to want to have them come in fairly regularly early on to ensure that they are tolerating it. Did you see the AEs in the PI? Akathisia? Parkinsonism? These are, of course, thinks that should not be a huge surprise with any antipsychotics - however, it may give someone pause before putting it in someone's body for 90 days. I think they will be VERY cautious. I think they will have more than just a medication checkpoint - it could be a very positive enhancement to their thereapeutic alliance. Look, it's easy to poke holes because WE don't have it. How about, rather than poking holes, think about how you might sell against it without going off label or falling into a compliance trap.
 






Top Bottom
Back
Quote